Use of radiation and a slow-release cisplatin formulation for treatment of canine nasal tumors

• Published in: Veterinary radiology & ultrasound Vol. 45; no. 6; pp. 577 - 581
• Main Authors: Lana, S.E, Dernell, W.S, Lafferty, M.H, Withrow, S.J, LaRue, S.M
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Inc 01.11.2004
• Subjects: Adenocarcinoma - therapy; Adenocarcinoma - veterinary; Animals; Antineoplastic Agents - administration & dosage; canine; Carcinoma, Squamous Cell - therapy; Carcinoma, Squamous Cell - veterinary; chemotherapy; cisplatin; Cisplatin - administration & dosage; Colorado - epidemiology; Combined Modality Therapy; Delayed-Action Preparations; Dog Diseases - mortality; Dog Diseases - pathology; Dog Diseases - therapy; Dogs; Female; Male; nasal tumor; Neoplasm Staging - veterinary; neoplasms; nose; Nose Neoplasms - therapy; Nose Neoplasms - veterinary; radiation; radiotherapy; Radiotherapy, Adjuvant; Records as Topic - veterinary; Retrospective Studies; Sarcoma - therapy; Sarcoma - veterinary; Survival Analysis; Colorado
• ISSN: 1058-8183; 1740-8261
• DOI: 10.1111/j.1740-8261.2004.04100.x

The purpose of this study was to evaluate the combined use of radiation and a slow‐release cisplatin chemotherapy formulation for treatment of malignant nasal tumors in dogs. In this retrospective analysis, 51 dogs were evaluated with respect to treatment toxicity, tumor type, stage of disease, cribriform plate involvement, and overall survival. In general, treatment was well tolerated. Mean and median survival as assessed by the Kaplan–Meier product limit method was 570 and 474 days, respectively. No other factors, including tumor type, stage of disease, or cribriform plate invasion had a significant impact on survival. In conclusion, a combination of slow release cisplatin chemotherapy and radiation for the treatment of canine nasal tumors is well tolerated. Results of this analysis warrant further study to elucidate possible other beneficial radiation potentiating drugs and dosing schedules.